Introduction
The programmed cell death, or apoptosis is a highly regulated process that is essential for the development and tissue homeostasis within all multicellular organisms. Diverse stimuli such as growth factor withdrawal (Denmeade et al., 1997) , deregulation of the cell cycle (Basu et al., 2002; Brady and Gil-Gomez, 1999; Haldar et al., 1997 Haldar et al., , 1998 Yamamoto et al., 1999; Ahmad et al., 2000) , DNA damage (Amundson et al., 1998) or death receptor-ligand interaction (Ashkenazi and might be responsible for initiating the apoptotic cascade. These pro-apoptotic signals induce several early events that converge by activating a common biochemical pathway, which then leads to the execution of apoptosis. Mitochondrion appears to be a core component of the cell death machinery (Zamzami and Kroemer, 2001) . Several cell death signals have been reported to release cytochrome c from mitochondria into the cytosol (Green and Reed, 1998; Andreas et al., 2000) . Released cytochrome c (also known as apoptosis protease activating factor-2) then binds to Apaf-1 (apoptosis protease activating factor-1) to form an apoptosome complex with procaspase-9 in an energy dependent manner (Li et al., 1997) . Subsequently activated caspase-9 triggers downstream caspases such as caspases-3 and -7 (Srinivasula et al., 1998 (Srinivasula et al., , 2001 Pan et al., 1998) . These downstream caspases, through the cleavage of several death substrates, are believed to cause execution of cell death. The pro-apoptotic members of Bcl-2 family (Basu and Haldar, 1998a; Vaux and Korsmeyer, 1999; Reed, 1995) were previously shown to be inducers of mitochondrial damage in speci®c death signaling pathways. Bax translocates from cytosol to mitochondria during apoptosis through an unidenti®ed mechanism (Wolter et al., 1997) . During Fas induced apoptosis Bid is cleaved by caspase-8 and the truncated C-terminal fragment of Bid also translocates from cytosol to mitochondria (Li et al., 1998) to release cytochrome c. However, reports are available suggesting that apoptosis can also be triggered independent of cytochrome c release from mitochondria (Kitagawa et al., 1999; MacDonald et al., 1999) .
Studies during the last decade have revealed 2-methoxyestradiol (2-ME) as a promising anti-angiogenic and anticancer agent (Pribluda et al., 2000) . The anti-proliferative activity of 2-ME in various tumor cell lines arises mainly from triggering of apoptosis Lin et al., 2000; Schumacher et al., 1999) . In contrast to actively proliferating cells, quiescent cells are not responsive to cytotoxic eects of 2-ME (Fotsis et al., 1994) . Despite being an estrogen metabolite, the anti-proliferative activity of 2-ME is independent of the presence of estrogen receptor (Martucci, 1983; Martucci and Fishman, 1979; Maclusky et al., 1983) . Recent studies have demonstrated that in human lung cancer cell lines, the eect of 2-ME is augmented by radiation exposure in a p53 dependent pathway (Huober et al., 2000) . In addition to its antiproliferative eect, 2-ME has been found to regulate various steps in the angiogenesis cascade such as migration, invasion, collagen matrix and tubule formation (Pribluda et al., 2000) . Several studies provide considerable evidence for its anti-tumor ability. 2-ME can target both the tumor cells and the endothelial cell compartment of a growing tumor. In human neuroblastoma xenograft model in mice 2-ME induced tumor cell death by the inhibition of tumor angiogenesis (Wassberg, 1999) . Besides primary tumors, 2-ME can eectively control metastatic invasion of cancer (Katotaka et al., 1998) .
In pursuit to unravel possible mechanism of action of 2-ME, several molecular targets including reactive oxygen species (Lin et al., 2000) , cell cycle kinases and regulators (Lottering et al., 1996; Zoubine et al., 1999) , transcription factor modulators (Yue et al., 1997) , p53, tubulin etc. (Mukhopadhyay and Roth, 1997; D'Amato et al., 1994; Hamel et al., 1996) have been proposed. In breast cancer cells, the treatment of 2-ME caused cell cycle dependent alteration in the level of cyclic-AMP accompanied by changes in the phosphorylation pattern of various proteins (Lottering et al., 1996) . 2-ME is also known to up regulate DR5 (death receptor) and sensitizes cells to TRAIL induced apoptosis (Ibrahim et al., 2001) . Furthermore, similar to other microtubule inhibitors, 2-ME treatment can trigger Bcl2 phosphorylation and apoptosis in erythromyeloid K562 cells (Attala et al., 1998) . The unique feature of this compound is that it speci®cally aects the cancer cells with no eect on normal cells (Seegers et al., 1997) , thus increasing its therapeutic index.
In the present study, we have been interested in unraveling the potential downstream eector of 2-ME triggered apoptotic signaling pathway in pancreatic cancer. Pancreatic cancer cells are usually resistant to conventional apoptosis-inducing agents. Irradiation and cytotoxic chemotherapy alone or in combination have only a minor in¯uence on survival (Abe et al., 2000) . Despite several hypotheses, the genetic changes in pancreatic cancer that prevent the activation of apoptosis in response to a variety of stimuli, still remains enigmatic.
In this study, we performed experiments to determine whether the mitochondrial pathway is involved in 2-ME mediated apoptosis of pancreatic carcinoma cell lines. Our results reveal that 2-ME activated apoptosis in pancreatic cancer induces a cascade of events that involves post-translational modi®cation of pro-apoptotic protein such as Bid cleavage, translocation of Bcl-2 family protein Bax to mitochondria, cytochrome c release into the cytosol and activation of apoptosis executioner caspase-3.
Results

Effect of 2-ME on clonogenic cell survival in soft agar
The ability of transformed cells to grow under anchorage-independent conditions is one of the few in vitro properties that is highly correlated with the malignant phenotype in vivo (Khan and Singh, 1979) . The antiproliferative property of 2-ME was tested by soft agar colony formation assay using PANC-1 cells. Single cell suspensions were mixed with 0.35% agar in culture medium with or without 2-ME. The mixture was layered on top of a solidi®ed bottom agar. After 3 weeks, plates were stained with crystal violet and visualized under phase contrast microscope. As shown in Figure 1 , control plates showed larger size colonies in contrast to 2-ME treated plates. Not only 2-ME can reduce the size of the colonies but also reduced the total number of colonies formed (approximately 30% of control). These data suggest that 2-ME can exert antitumor activity on PANC-1 cells.
2-ME and apoptosis in pancreatic cancer
Next, we were interested to see whether the antiproliferative activity of 2-ME results from the induction of cell death program. The potential apoptosis inducing eect of 2-ME was tested on dierent actively proliferating human pancreatic cancer cell lines that exhibit aggressive clinical behavior. The dierent pancreatic cancer cell lines diered in their response Figure 1 Eect of 2-ME on clonogenic cell survival in soft agar.
PANC-1 cells were tested for the ability to produce colonies in soft agar in the presence or absence of 5 mM 2-ME as described in Materials and methods. After 3 weeks, plates were stained with crystal violet. Phase contrast microscopic images shown are representative of typical patterns most commonly observed in these experiments 2-ME triggered apoptosis in pancreatic cancer S Qanungo et al to 2-ME-induced apoptosis. The caspase family of cysteine proteases plays a key role in mediating apoptosis through proteolysis of speci®c target. Among the targets are Poly ADP Ribose Polymerase (PARP) and nuclear lamins. PARP is a 116 kDa nuclear protein that is speci®cally cleaved by caspase 3 into a signature 85 kDa fragment (Haldar et al., 1997 (Haldar et al., , 1998 . In response to 2-ME treatment, pancreatic carcinoma cells MIA PaCa-2 showed elevated level of 85 kDa fragmented PARP, which is considered to be the hallmark of apoptosis. On the other hand, PANC-1 cells (isolated from ductal carcinoma of pancreas) were moderately responsive to 2-ME induced apoptosis. Time-course studies ( Figure 2a ) in MIAPaCa-2 and PANC-1 cells reveal that PARP cleavage reaches a peak at approximately 48 ± 72 h exposure of 2-ME. Interestingly, another pancreatic carcinoma cell line Hs 766T derived from lymph node metastasis were nonresponsive to 2-ME induced PARP cleavage (not shown). Since PARP is activated in the presence of nicked or damaged DNA, we stained the control and 2-ME treated cells with 4, 6-diamidino-2-phenylindole, DAPI (Haldar et al., 1995; Soengas et al., 2001) . MIA PaCa-2 cells, which underwent enhanced PARP cleavage, also exhibited the most number of apoptotic nuclei in comparison to PANC-1 cells (42% vs 25%) when both were treated with 2-ME for 48 h. The nonresponsive character of metastatic pancreatic cancer cell line Hs 766T to 2-ME was also re¯ected by the negligible presence of chromatin condensation ( Figure  2b ). Moreover, caspase inhibitor z-VAD blocked 2-ME triggered apoptosis in MIA PaCa-2 cells (Figure 2c )
Apoptosis regulatory proteins in pancreatic cancer
In order to understand the dierential response of pancreatic cancer cells to the same agent 2-ME, we initially focused our attention to investigate the status of anti-and pro-apoptotic proteins in these cells Western blot of 2-ME treated cell lysate using monoclonal antibody against PARP. Cells were exposed to 2-ME for the indicated time points. (b) Apoptotic cell death visualized by DAPI staining. Cells were exposed to 5 mM 2-ME for 48 h. (c) Caspase inhibitor z-VAD can block 2-ME induced apoptosis. Cells were pretreated with 500 nM z-VAD for 1 h followed by co-incubation with 5 mM 2-ME for 24 h. Figure  3d ,f). Apparently, the higher level of expression of proapoptotic proteins than anti-apoptotic counterparts in MIA PaCa-2 cells correlates positively with enhanced apoptosis in response to 2-ME.
2-ME induced phosphorylation of Bcl-x L
Phosphorylation of anti-apoptotic proteins such as Bcl-2, Bcl-x L , or Mcl-1 in the presence of microtubule inhibitors can negatively regulate their anti-apoptotic functions (Haldar et al., 1995 (Haldar et al., , 1996 (Haldar et al., , 1997 (Haldar et al., , 1998 Yamamoto et al., 1999; Srivastava et al., 1998 Srivastava et al., , 1999 Poruchynsky et al., 1998; Domina et al., 2000) . In contrary to MIA PaCa-2 cells, PANC-1 and CFPAC-1 cells express signi®cant amount of Bcl-x L . 2-ME and its estrone derivatives can trigger Bcl-2/Bcl-x L phosphorylation in breast cancer or leukemic cells (Attala et al., 1998; MacCarthy-Morough et al., 2000) . We thought perhaps 2-ME mediated apoptosis might occur through Bcl-x L phosphorylation in these pancreatic cancer cells. Both of these cells were exposed to a variety of antimicrotubule agents such as Taxol, nocodazole as well as 2-ME. Like Taxol or nocodazole, the slower mobility form of Bcl-x L was evident in the presence of 2-ME in both PANC-1 and CFPAC-1 cells (Figure 4a ). That the slower mobility form of Bcl-x L is phosphorylated can be suggested by its abolition due to lphosphatase treatment (Figure 4b ). Our data is further strengthened by the return of the retarded form of Bclx L in the presence of l-phosphatase inhibitor Naorthovanadate. It is noteworthy that no Bcl-2/Bcl-x L phosphorylation was detectable in either MIA PaCa-2 (not shown) or Hs 766T cells (Figure 4c ).
Differential patterns of cell cycle arrest due to 2-ME exposure
Bcl-x L /Bcl-2 phosphorylation normally occurs in cells arrested at G2-M phase of cell cycle by antimicrotubule agents (Haldar et al., 1997 (Haldar et al., , 1998 Poruchynsky et al., 1998; Srivastava et al., 1998 Srivastava et al., , 1999 Yamamoto et al., 1999) . Accordingly, our interest was to test the cell cycle distribution in 2-ME challenged PANC-1, MIA PaCa-2 and Hs 766T cells. The¯ow cytometric analysis reveals that a considerable fraction (approximately 90%) of the 2-ME-treated PANC-1 cells accumulate as G2-M population compared to control (untreated) cells (Figure 5b ). However, an interesting phenomenon occurs in the case of MIA PaCa-2 cells. 2-ME exposure to these cells leads to two overlapping peaks appearing in the G2-M-S-phase region ( Figure  5a ). This indicates that the treated MIA PaCa-2 cells enter G2-M, remain there for a very short time and then exit as smaller tetraploid cells with higher DNA Eect of 2-ME on anti-apoptotic protein Bcl-x L phosphorylation in pancreatic cancer cells. CFPAC-1, PANC-1 and Hs 766T cells were treated with 1 ± 5 mM 2-ME for 24 h. One mM Taxol (Tx) and 0.1 mM Nocodazole (Noc) were used as positive control. Lane C (a and c) represents control cells. (a) Bclx L phosphorylation in CFPAC-1 and PANC-1 cells. (b) lphosphatase can abolish 2-ME induced modi®ed form of Bcl-x L while Na-orthovanadate can revert the eect of l-phosphatase 2-ME triggered apoptosis in pancreatic cancer S Qanungo et al content. This tetraploid fraction of cells, when further sorted was found to exhibit prolonged accumulation in the G1-S phase. Hs 766T cells, which do not respond to 2-ME induced apoptosis, did not demonstrate any change in cell cycle distribution (Figure 5c ). These results imply that 2-ME induces apoptosis of PANC-1 cells by causing G2-M arrest, whereas MIA PaCa-2 cells are driven towards apoptosis by G1-S arrest.
Mitochondrial damage
Mitochondria have been implicated as an important sensor and ampli®er in intracellular death signaling pathways. Mitochondrial damage as revealed by disruption of the outer membrane and the release of pro-apoptotic factors such as cytochrome c is evident during early apoptosis. 2-ME triggered apoptosis is also mitochondria dependent as indicated by the enrichment of cytochrome c in the cytosol of both MIA PaCa-2 and PANC-1 cells (Figure 6a ). No enrichment of cytochrome c was observed in the cytosol of Hs 766T cells (non-responsive to 2-ME induced apoptosis). Following 2-ME exposure pancreatic cancer cells behaved dierently in regard to the translocation of Bax. While we could not detect Bax enrichment in mitochondria of 2-ME treated PANC-1 cells (not shown), signi®cant increase in Bax level was noted in that of MIA PaCa-2 cells (Figure 6b ). Our results are in conformity to that of Karpinich et al. (2002) reporting similar enrichment of Bax in the mitochondria of etoposide treated L929 ®broblasts. Of note, the non-responsive Hs 766T cells do not exhibit any change in the cytosolic Bax following 2-ME exposure (Figure 6b ). In the case of another pro-apoptotic member, Bid, 2-ME exposure results in signi®cant disappearance of intact 21 kDa Bid from the total cellular extract of both MIA PaCa-2 (Figure 7a ) and PANC-1 (not shown) cells. But the same treatment does not yield any alteration of intact Bid in the case of Hs 766T cells (Figure 7a ). The change in the level of Bid in the whole cell extract was also re¯ected in the isolated cytosolic fractions of both MIA PaCa-2 and PANC-1 cells (Figure 7b ). This decrease in Bid protein following 2-ME exposure is quite comparable with curcumin induced Bid cleavage in HL-60 cells (Anto et al., Cell cycle analysis of human pancreatic cancer cell lines after treatment with 2-ME. MIA PaCa-2, PANC-1 and Hs 766T cells were treated with 5 mM 2-ME for 17 h and then analysed for cell cycle distribution by¯ow cytometry. (a) 2-ME treated MIAPaCa-2 cells exhibited two overlapping peaks (I) in the G2-M region. The second peak when further sorted found to be tetraploid G1 (II). (b) Normal cycling cells in control PANC-1 and accumulation of cells at G2-M phase following 2-ME treatment. (c) No change in cell cycle distribution following 2-ME treatment in Hs 766T cells 2002). Similar to our observation the decrease of Bid level was also noted in the case of curcumin-triggered apoptosis of myeloid leukemia cells (Anto et al., 2002) .
Post-mitochondrial apoptotic regulators
During apoptosis caspase-9 and its cofactor Apaf-1 can be the essential downstream eectors of cell death. The Apaf-1/caspase-9 apoptosome complex further activates downstream caspase-3, which then cleaves nuclear substrates such as PARP, lamins etc. Among the cell lines tested, Apaf-1 is expressed at highest level in MIA PaCa-2 cells (data not shown). Correlatively, these cells are also most susceptible to 2-ME induced apoptosis. Caspase-3 activation was also monitored in these cells. For activation of caspase-3, initially inactive form of caspase-3 or procaspase-3 needs to be cleaved. As shown in Figure 8b , the down regulation of procaspase-3 is signi®cantly evident in 2-ME challenged MIAPaCa-2 cells which is correlative of drastic cleavage of PARP, a key substrate of apoptosis executioner caspases. The moderate cleavage of procaspase-3 was observed in 2-ME treated PANC-1 cells (Figure 8a) . Notably, Hs 766T cells (Figure 8a ) that are not responsive to 2-ME induced cell death also a b Figure 6 Mitochondria dependent apoptosis by 2-ME in pancreatic cancer cells. Cells were exposed to 5 mM of 2-ME for 48 h. Mitochondria and cytosol fractions isolated from cells were subjected to immunoblot analysis with cytochrome c (a) and Bax (b) antibodies. (a) 2-ME can enrich cytochrome c in the cytosol of pancreatic cancer cells. (b) 2-ME can translocate pro-apoptotic protein Bax from cytosol to mitochondria in MIA PaCa-2 cells a b Figure 7 Decrease in 21 kDa Bid in the total cellular extract and the cytosolic fraction of 2-ME challenged pancreatic cancer cells. Total cellular extract (a) and cytosolic fractions (b) of control (c) and 24 h 2-ME treated cells were subjected to immunoblot analysis with Bid peptide polyclonal antibody do not demonstrate any cleavage of procaspase-3. Interestingly, caspase inhibitor z-VAD can block 2-ME triggered decrease of procaspase-3 (Figure 8b ).
Discussion
Carcinoma of the pancreas is one of the most aggressive forms of malignancies with an extremely poor prognosis. Apparently, the improvement of treatment options for pancreatic cancer is warranted. The present study provides a signi®cant new rationalization for the mechanism of 2-ME induced cell death in the case of pancreatic cancer. 2-ME appears to exert diverse apoptotic signaling in dierent pancreatic cancer cells. Studies on the eect of 2-ME on mitochondria reveal the translocation of a proapoptotic protein Bax from cytosol to mitochondria in 2-ME responsive cells. Also, the release of cytochrome c into the cytosol was noted in these cells.
The anti-apoptotic protein Bcl-x L is expressed in a greater extent in PANC-1 cells than that of MIA PaCa-2. Interestingly, mitotic arrested PANC-1 cells undergo Bcl-x L phosphorylation in response to 2-ME with simultaneous apoptosis. Microtubule inhibitor induced Bcl-2/Bcl-x L phosphorylation is known to be detrimental to its anti-apoptotic function (Haldar et al., 1995 (Haldar et al., , 1997 (Haldar et al., , 1998 Poruchynsky et al., 1998; Srivastava et al., 1998 Srivastava et al., , 1999 Yamamoto et al., 1999) . We have identi®ed two dierent signaling pathways of 2-ME action in pancreatic cancer cells. In PANC-1 cells, G2-M arrest followed by anti-apoptotic protein Bcl-x L phosphorylation provides potential means for inducing programmed cell death while MIA PaCa-2 cells are driven towards apoptosis by G1-S arrest without any phosphorylation of Bcl-2/Bcl-x L . But in both cases, we have observed release of cytochrome c from mitochondria. The release of cytochrome c has been postulated to be an important event for activation of downstream caspases and apoptotic cell death. Our data presented here are also consistent with the hypothesis that mitochondria are important regulator of 2-ME induced apoptosis.
The mitochondrion is thought to be a pivotal decision center in a variety of apoptotic responses (Martinou and Green, 2001; Vander Heiden and Thompson, 2001 ). The Bcl-2 family proteins control the permeability of the outer mitochondrial membrane (OMM). The pro-apoptotic members of the Bcl-2 family such as Bax, Bid or Bak either reside on the outer mitochondrial membrane or in the cytosol (Zamzami and Kroemer, 2001) . In response to environmental cues, the pro-apoptotic proteins containing only BH3 domains undergo post-translational modi®cations, which enables them to interact with other Bcl2 family proteins. For example, the cleavage of a pro-apoptotic protein Bid by caspase-8 and the interaction of truncated Bid with Bax, either in the cytosol or on the mitochondrial surface, render conformational changes in Bax. Bax then inserts itself into OMM where it oligomerizes and facilitates release of cytochrome c from the intermembrane mitochondrial space (Martinou and Green, 2001) In the case of both PANC-1 and MIA PaCa-2 cells, we observed the disappearance of intact 21 kDa Bid following exposure to 2-ME. These results are in agreement with a previous observation reporting 2-ME induced caspase-8 activation in gastric carcinoma cells (Lin et al., 2001) . Furthermore, the enrichment of Bax in isolated mitochondria and its simultaneous wane in the cytosol of 2-ME treated MIA PaCa-2 cells are indicative of its translocation to mitochondria. However, in PANC-1 cells we were unable to detect translocation of Bax to mitochondria following 2-ME exposure. Our inability to detect translocation of Bax to mitochondria in 2-ME treated PANC-1 cells might be attributed to the low-level expression of Bax in this cell line as compared to MIA PaCa-2 cells (Figure 3) . It is known that cleaved Bid can also translocate and insert into the outer mitochondrial membrane and activate other members of Bax subfamily proteins like Bak, which is anchored to the mitochondrial membrane. Apparently in 2-ME exposed PANC-1 cells, conformational change and oligomerization of Bak might permeabilize the outer mitochondrial membrane to release cytochrome c.
Thus we have identi®ed some of the downstream eectors of 2-ME induced apoptosis in pancreatic cancer cells. This knowledge of the mechanism of a b Figure 8 Diminished procaspase-3 level following 2-ME exposure can be restored by caspase inhibitor z-VAD. (a) Cell lysate from control and 48 h 2-ME exposed cells were subjected to immunoblot analysis with caspase-3 antibody. Note that the level of procaspase-3 in both PANC-1 and MIA PaCa-2 cells is decreased following 2-ME treatment, whereas non responsive Hs 766T cells are unaected. (b) Eect of caspase inhibitor z-VAD on 2-ME induced decrease of procaspase-3 level. MIA PaCa-2 cells were pretreated with 500 nM z-VAD for 1 h followed by coincubation with 5 mM 2-ME for 24 h action of 2-ME might have important implications from therapeutic standpoint.
Materials and methods
Anti-peptide rabbit antisera speci®c for Bax have been described previously (Haldar et al., 1996) . Apaf-1 and Bcl-2 antibodies were purchased from Upstate Biotechnology (New York, USA). Monoclonal antibodies against PARP, Bcl-x L and cytochrome c were obtained from Pharmingen (USA). Goat polyclonal antibody against human Bid as well as Mcl-1, Bad rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology (USA). Survivin and Caspase-3 antibodies were available from Novus Biologicals and Transduction Laboratories respectively. The antibodies against b-actin and a-tubulin were obtained from Sigma Chemical Co. (USA). Caspase inhibitor z-VAD was purchased from Calbiochem (USA).
Human pancreatic cancer cell lines MIA PaCa-2, PANC-1, AsPC-1, BxPC-3, Hs 766T, SU86.86 and CFPAC-1 were grown in RPMI supplemented with 10% FBS and 50 mg/ml gentamicin at 378C in a 5% CO 2 humidi®ed atmosphere.
Cells were treated with speci®ed concentrations of 2-ME for designated time-periods. Following treatment, total cellular proteins were extracted. After normalization for total protein content, the resulting lysates were subjected to SDS ± PAGE and immunoblotting (Basu and Haldar, 1998b) . Equal protein loading was veri®ed routinely by Ponceau S staining of the nitrocellulose membrane. Immunodetection was accomplished by enhanced chemilumiscence method (Amersham/Pharmacia Biotech).
Chromatin condensation was determined by DAPI¯uor-escence (Haldar et al., 1995) . Soft agar assay for clonogenic cell survival was performed according to Soengas et al. (1999) . Cell cycle analysis was done by¯ow cytometry as described before (Haldar et al., 1997 (Haldar et al., , 1998 . Isolation of a highly enriched mitochondrial as well as cytosolic fraction of various pancreatic cancer cells was carried out using a kit from BioVision, Inc. following manufacturer's protocol.
